 MELBOURNE, Australia, July 23, 2020 GLOBE NEWSWIRE -- Immuron Limited ASX: IMC; NASDAQ: IMRN, the Company, an Australian biopharmaceutical company focused on developing and commercializing oral immunotherapeutics for the prevention and treatment of gut mediated pathogens, today announced the closing of its previously announced registered direct offering of 1,066,668 American Depositary Shares ADSs, each representing forty 40 of the Companys ordinary shares, at a purchase price of 18.75 per ADS for gross proceeds of approximately US20.0 million. H.C. Wainwright Co. acted as the exclusive placement agent for the offering.The Company intends to use the net proceeds from this offering to fund Immurons research and development, preclinical and clinical programs, support marketing initiatives surrounding the Companys flagship product Travelan and provide ongoing working capital for the Company.The Securities and Exchange Commission declared effective a registration statement on Form F-3 File No. 333-230762 relating to these securities on April 17, 2019. A final prospectus relating to this offering has been filed with the Securities and Exchange Commission. The offering was made only by means of a prospectus. Electronic copies of the final prospectus relating to the offering may be obtained on the SECs website at or by contacting H.C. Wainwright Co., LLC at 430 Park Avenue, 3rd Floor, New York, NY 10022, by phone at 646 975-6996 or e-mail at press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.This release has been authorised by the directors of Immuron Limited.COMPANY CONTACT: Dr Jerry Kanellos, Ph.D. Chief Executive Officer Ph: 61 03 9824 5254 INVESTOR RELATIONS: Dave Gentry, CEO RedChip Companies Inc. 407-491-4498 About Immuron Immuron Limited ASX: IMC, NASDAQ: IMRN, is an Australian biopharmaceutical company focused on developing and commercializing orally delivered targeted polyclonal antibodies for the treatment of inflammatory mediated and infectious diseases. Immuron has a novel and safe technology platform with one commercial asset generating revenue. In Australia, Travelan is a listed medicine on the Australian Register of Therapeutic Goods AUST L 106709 and is indicated to reduce the risk of Travellers Diarrhea, reduce the risk of minor gastro-intestinal disorders and is antimicrobial. In Canada, Travelan is a licenced natural health product NPN 80046016 and is indicated to reduce the risk of Travellers Diarrhea. In the U.S., Travelan is sold as a dietary supplement for digestive tract protection in accordance with section 403 r6 of the Federal Drug Administration FDA.About TravelanTravelan is an orally administered passive immunotherapy that prophylactically reduces the likelihood of contracting travelers diarrhea, a digestive tract disorder that is commonly caused by pathogenic bacteria and the toxins they produce. Travelan is a highly purified preparation of hyper immune bovine antibodies and other factors, which when taken with meals bind to diarrhea-causing bacteria and prevent colonization and the pathology associated with travelers diarrhea. In Australia, Travelan is a listed medicine on the Australian Register for Therapeutic Goods AUST L 106709 and is indicated to reduce the risk of Travelers Diarrhea, reduce the risk of minor gastro-intestinal disorders and is antimicrobial. In Canada, Travelan is a licensed natural health product NPN 80046016 and is indicated to reduce the risk of Travelers Diarrhea. In the U.S., Travelan is sold as a dietary supplement for digestive tract protection.About Travelers diarrheaTravelers diarrhea is a gastrointestinal infection with symptoms that include loose, watery and occasionally bloody stools, abdominal cramping, bloating, and fever, Enteropathogenic bacteria are responsible for most cases, with enterotoxigenic Escherichia coli ETEC playing a dominant causative role. Campylobacter spp. are also responsible for a significant proportion of cases. The more serious infections with Salmonella spp. the bacillary dysentery organisms belonging to Shigella spp. and Vibrio spp. the causative agent of cholera are often confused with travelers diarrhea as they may be contracted while travelling and initial symptoms are often indistinguishable.For more information visit: STATEMENTS:This press release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, each as amended. Such statements include, but are not limited to, statements regarding the use of proceeds as well as any statements relating to our growth strategy and product development programs and any other statements that are not historical facts. Forward-looking statements are based on managements current expectations and are subject to risks and uncertainties that could negatively affect our business, operating results, financial condition and stock value. Factors that could cause actual results to differ materially from those currently anticipated include: market and other conditions, risks relating to our growth strategy; our ability to obtain, perform under and maintain financing and strategic agreements and relationships; risks relating to the results of research and development activities; risks relating to the timing of starting and completing clinical trials; uncertainties relating to preclinical and clinical testing; our dependence on third-party suppliers; our ability to attract, integrate and retain key personnel; the early stage of products under development; our need for substantial additional funds; government regulation; patent and intellectual property matters; competition; as well as other risks described in our SEC filings. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations or any changes in events, conditions or circumstances on which any such statement is based, except as required by law. 